Astria Therapeutics (ATXS) to Release Earnings on Monday

Astria Therapeutics (NASDAQ:ATXS) is expected to release its earnings data before the market opens on Monday, March 3rd. Analysts expect Astria Therapeutics to post earnings of ($0.45) per share for the quarter.

Astria Therapeutics Stock Performance

Shares of Astria Therapeutics stock opened at $6.81 on Monday. The stock’s fifty day moving average is $8.01 and its 200 day moving average is $10.01. The stock has a market cap of $384.29 million, a P/E ratio of -3.26 and a beta of 0.67. Astria Therapeutics has a one year low of $6.64 and a one year high of $16.90.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Citizens Jmp raised Astria Therapeutics to a “strong-buy” rating in a report on Friday, January 31st. JMP Securities assumed coverage on Astria Therapeutics in a report on Friday, January 31st. They set an “outperform” rating and a $26.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a report on Thursday, January 23rd. Finally, Oppenheimer raised their price target on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $25.67.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.